Sphingosine 1-phosphate (S1P) functions not only as a bioactive lipid molecule but also as an important intermediate of the sole sphingolipid-to-glycerolipid metabolic pathway. However, the precise reactions and the enzymes involved in this pathway remain unresolved. We report here that yeast HFD1 and the Sjögren-Larsson syndrome (SLS)-causative mammalian gene ALDH3A2 catalyze conversion of the S1P degradation product hexadecenal to hexadecenoic acid. The absence of ALDH3A2 in CHO-K1 mutant cells caused abnormal metabolism of S1P/hexadecenal to ether-linked glycerolipids. Moreover, we demonstrate that yeast Faa1 and Faa4 and mammalian ACSL family members are acyl-CoA synthetases involved in the sphingolipid-to-glycerolipid metabolic pathway, and that hexadecenoic acid accumulates in faa1 faa4 mutant cells. These results unveil the entire S1P metabolic pathway: S1P is metabolized to glycerolipids via hexadecenal, hexadecenoic acid, hexadecenoyl-CoA, and palmitoyl-CoA. From our results we propose a possibility that accumulation of the S1P metabolite hexadecenal is contributed to the pathogenesis of SLS.
INTRODUCTION
Sphingosine 1-phosphate (S1P) plays important roles as an intracellular signaling molecule and as a ligand for G protein-coupled receptors (S1P 1 to S1P 5 ) (Kihara et al., 2007; Pyne and Pyne, 2011) . The FDA-approved immunomodulator FTY720 undergoes in vivo phosphorylation then mimics S1P ligand functions (Pyne and Pyne, 2011) . S1P also functions as an intermediate in the metabolism of sphingolipids (Kihara et al., 2007) , which function in biological processes and are major components of eukaryotic plasma membranes (Kihara et al., 2007 ; Kolesnick and Krönke, 1998) .
Sphingolipid metabolism involves salvage pathways that generate the sphingolipid backbone ceramide (Cer) and/or its component sphingosine (Sph) , which are then utilized to rebuild sphingolipids. Alternatively, the Sph is phosphorylated by a Sph kinase to form S1P (Kihara et al., 2007) . S1P can be metabolized to glycerolipids through degradation involving a S1P lyase, which cleaves S1P into a fatty aldehyde (hexadecenal) and phosphoethanolamine (Kihara et al., 2007) (Figure 1A ). Disorders in sphingolipid metabolism, termed sphingolipidoses, are well known, with ~40 having been identified thus far (Sillence and Platt, 2003) . However, to date, no such disorder has been associated with S1P or its metabolism.
Beyond the generation of hexadecenal, no precise metabolic pathway has been determined for S1P-to-glycerolipid conversion, and little is understood regarding the enzymes involved or any disorders arising from their disruption. Considering that aldehyde molecules are highly reactive, for example with primary amines (James and Zoeller, 1997) , it would be expected for aberrations in S1P metabolism to lead to pathological disorders.
Cer comprises a long-chain base (LCB) attached to fatty acid (FA) via an amide bond.
Sph, the major LCB in mammals, contains a trans-double bond between C4 and C5, while another LCB, dihydrosphingosine (DHS), has no double bond ( Figure 1A ). DHS is generated via the de novo sphingolipid synthesis pathway and is metabolized similarly to S1P (Figure   4 1A). The metabolic pathway of DHS1P has already been identified (Kihara et al., 2007) ( Figure 1A ), yet it is unknown when and how the trans-double bond derived from S1P is converted to the saturated bond. Moreover, the fatty aldehyde dehydrogenase (FALDH), the acyl-CoA synthetase (ACS), and the saturating enzyme involved in S1P/DHS1P metabolic pathway all remain unidentified.
ALDH3A2 is an FALDH that exhibits activity toward saturated and unsaturated aliphatic aldehydes of 6 to 24 carbons in length (Kelson et al., 1997) . Mutations in the ALDH3A2 gene cause Sjögren-Larsson syndrome (SLS), the neurocutaneous disorder characterized by congenital ichthyosis, mental retardation, and spasticity (De Laurenzi et al., 1996; Rizzo, 2007) . Although accumulated fatty aldehydes in SLS patients are thought to be responsible for the pathology, the source of the accumulation remains unclear. In the presented study, we have identified ALDH3A2 as the FALDH active within the S1P metabolic pathway.
ACSs catalyze the conversion of FAs to their activated forms, i.e., acyl-CoAs. The yeast Saccharomyces cerevisiae and mammals have 7 and 26 ACSs, respectively (Black and DiRusso, 2007; Watkins et al., 2007) . In the presented study, we identified Faa1 and Faa4 in yeast and ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6 in mammals as ACSs responsible for S1P/DHS1P metabolic pathways. We also demonstrated that hexadecenoic acid is the intermediate of S1P metabolism. From these results, we determined the entire S1P metabolic pathway. Figure 2A and Figure S1A ). In contrast, DHS was not converted to glycerolipids in the dpl1 cells (Figure 2A ), as expected from its function in the LCB/LCBP metabolic pathway ( Figure 1B ).
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RESULTS
Yeast
Of the 8 aldehyde dehydrogenase mutants, only the hfd1 cells exhibited a deficiency in DHS-to-glycerolipid conversion (Figure 2A ), indicating that Hfd1 is the FALDH involved in the metabolism of DHS/DHS1P in yeast. In the hfd1 cells, hexadecanol but not hexadecanal accumulated ( Figure S1B ), suggesting that the some unmetabolized hexadecanal was reduced to hexadecanol. However, the accumulated hexadecanol levels were lower than would be expected when considering the sum of glycerolipid levels in wild type cells ( Figure 2A and Figure S1A and B). We speculate that most of the unmetabolized hexadecanal might have reacted with several cellular components having primary amines before being converted to hexadecanol.
To date, no function for Hfd1 has been identified. Homology searches revealed that, 6 among mammalian aldehyde dehydrogenases, Hfd1 shares the highest sequence similarity with mammalian ALDH3A2 (30.0% identity and 50.6% similarity). The ALDH3A2 gene is known to be responsible for the neurocutaneous disorder SLS (Rizzo, 2007) . ALDH3A2
reportedly exhibits activity toward saturated and unsaturated aliphatic aldehydes ranging from 6 to 24 carbons in length (Kelson et al., 1997 H atom is removed during S1P conversion to hexadecenal by S1P lyase ( Figure   S2A and B). In contrast, 4,5-3 H labeled DHS enables monitoring of its metabolism both to sphingolipids and to glycerolipids ( Figure S2A and B) . In a late 1960s study, [7-3 H]Sph administered intravenously to a rat was converted in the liver to both sphingolipids and glycerolipids, and the major Sph-derived FA in glycerolipids was palmitic acid (Stoffel and Sticht, 1967 Figure 3C ). In this experiment, half of the samples were treated with alkaline solution. Since ester linkages in glycerolipids are hydrolyzed by alkaline treatment, glycerolipid bands disappeared, while sphingolipid bands remained unchanged ( Figure 3C ).
Using another cell line, mouse embryonic carcinoma F9 cells, we repeated the labeling experiments. We also used F9 SPL -/-cells, which lack the S1P lyase SPL, as a negative control that cannot convert DHS or Sph to glycerolipids (Ikeda et al., 2005) . Again, Sph and DHS were similarly metabolized to sphingolipids and to glycerolipids in wild type F9 cells, but were metabolized only to sphingolipids in the SPL -/-cells ( Figure 3D ). Cer and glucosylceramide (GlcCer), observed at high levels after a 2 hr labeling period, had decreased by 24 hr. Instead, lactosylceramide (LacCer), which is a further metabolite of GlcCer, and the glycerolipids PE and PS/PI had increased. These results indicate that DHS and Sph are similarly metabolized in mammalian cells.
Natural LCBs found in the yeast S. cerevisiae include DHS and phytosphingosine ( Figure   1B ). Sph is not found in the yeast, yet the yeast can still use exogenously added Sph as a precursor for sphingolipids (Tani et al., 2006 was converted mainly to glycerolipids, with a small amount converted to sphingolipids ( Figure   4A ); it is possible that sphingolipid biosynthetic enzymes such as Cer synthase might have 8 lower activities toward Sph. Again, the DHS-to-glycerolipid conversion was Dpl1-and Hfd1-dependent ( Figure 4A ). This Sph-to-glycerolipid metabolic pathway was blocked in hfd1 cells as in dpl1 cells ( Figure 4A ), indicating that Hfd1 catalyzes not only conversion of hexadecanal derived from DHS1P to palmitic acid, but also that of hexadecenal (more precisely trans-2-hexadecenal) from S1P to hexadecenoic acid (trans-2-hexadecenoic acid).
We also observed accumulation of hexadecenol in the hfd1 cells ( Figure S1B ), which might reflect unmetabolized hexadecenal reduced to hexadecenol. Introduction of human ALDH3A2
cDNA into the hfd1 cells restored the Sph-to-glycerolipid conversion ( Figure 4B ), similar to results in the [4, H]DHS labeling experiment ( Figure 2B ). To date, the enzymatic activity of ALDH3A2 toward trans-2-hexadecenal has not been investigated. However, our results suggest that ALDH3A2 is active toward 2-trans-hexadecenal. To confirm this, we performed in vitro assays using affinity-purified 3xFLAG-ALDH3A2. ALDH3A2 did indeed exhibit FALDH activities toward both 2-trans-hexadecenal and hexadecanal, although its activity toward hexadecanal was ~2 fold higher than that toward 2-trans-hexadecenal ( Figure 4C ).
Sph was proven to be metabolized to palmitic acid in glycerolipids in mammals (Stoffel and Sticht, 1967) . However, it was unclear whether in yeast the FA in glycerolipids converted from Sph is also palmitic acid or if it is hexadecenoic acid still containing the 2-trans double bond. To examine the FA species in glycerolipids derived from Sph, lipids were extracted from wild type yeast cells labeled with [11, (Scarim et al., 1989) . This method can determine whether FA derived from Sph in yeast is saturated palmitic acid or unsaturated hexadecenoic acid. Control palmitic acid was indeed resistant to KIO 4 /KMnO 4 treatment, whereas hexadecenoic acid was sensitive ( Figure   4E ). Aldehyde molecules are toxic to cells due to their high reactivity (James and Zoeller, 1997) . We examined the toxicity of endogenously generated hexadecanal and hexadecenal by adding DHS or Sph to the medium of wild type, hfd1, or dpl1 yeast cells. The hfd1 cells were more sensitive both to DHS and to Sph, as compared to wild type cells ( Figure S3A and B). The dpl1 cells were also sensitive to DHS and Sph, but especially to Sph ( Figure S3A ).
However, in the dpl1 cells toxicities were caused by an accumulation of LCBPs and the more toxic effect of Sph reflects higher accumulation levels of S1P compared to DHS1P in the dpl1 cells ( Figure 4A ) (Zhang et al., 2001 ). In the hfd1 cells, both S1P and DHS1P levels were similar to those in wild type cells ( Figure 4A ), so the sensitivity to exogenous LCBs observed for these cells may be caused by toxicities of endogenously generated fatty aldehydes.
LCBs/LCBPs are Metabolized to Ether-linked Glycerolipids in ALDH3A2-deficient
CHO-K1 Cells
We next investigated the involvement of ALDH3A2 in LCB/LCBP metabolism using mammalian cells. FAA-K1A cells were isolated from CHO-K1 cells as a FALDH mutant cell line; these cells displayed ~10% of the FALDH activity compared to CHO-K1 cells (James and Zoeller, 1997) . RT-PCR revealed that ALDH3A2 mRNA was barely detectable in the Figure 4D and E). Considering that hexadecenoic acid is a substrate of the ACSs Faa1 and Faa4, the product should be hexadecenoyl-CoA. Thus, it is most probable that hexadecenoyl-CoA is converted to palmitoyl-CoA before incorporation into glycerolipids.
We next investigated the sensitivity of the faa1 faa4 cells to exogenous LCBs, and 13 compared it to that of the other tested mutants. In contrast to the hfd1 cells, the faa1 faa4 cells were not sensitive to exogenous DHS or Sph, indicating that accumulated hexadecenoic acid is not toxic to these cells ( Figure S3B ). Thus, toxic fatty aldehydes are detoxified by Hfd1.
Of the 26 mammalian ACSs, Faa1 and Faa4 share the highest homology with the ACSL subfamily members ACSL1, 3, 4, 5, and 6, with ACSL4 exhibiting the highest similarity overall (26.6% identity and 47.7% similarity to Faa1 and 30.3% identity and 47.9% similarity to Faa4). When these proteins were expressed in faa1 faa4 cells as N-terminally 3xFLAG tagged proteins, all restored Sph-to-glycerolipid conversion ( Figure 6E ). However, two other ACS subfamily members, ACSS1 and ACSM1, exhibited no activity, and restoration was weak for ACSL3, probably due to low expression levels ( Figure 6F ). These results indicate that ACSL family members can also convert hexadecenoic acid to hexadecenoyl-CoA, in a manner similar to that observed for yeast Faa1 and Faa4 .
DISCUSSION
Aside from its well-known function as a bioactive lipid molecule, S1P is also important as an intermediate in the sphingolipid-to-glycerolipid conversion pathway. However, certain steps in this metabolic pathway, and the metabolic enzymes involved with those steps, remain unresolved. At least three pathways were considered in studying the conversion of hexadecenal (the product of S1P by S1P lyase) to palmitoyl-CoA ( Figure S5 , Schemes 1 to 3). It is possible that hexadecenal is first converted to hexadecanal, then to palmitic acid, and finally to palmitoyl-CoA ( Figure S5 , Scheme 1). Alternatively, hexadecenal is converted to palmitoyl-CoA via hexadecenoic acid and hexadecenoyl-CoA (Scheme 2) or via hexadecenoic acid and palmitic acid (Scheme 3). Our results clearly indicate that Scheme 2 (also shown in Figure 7 ) is the actual S1P metabolic pathway. Aldehyde molecules are highly reactive, so they must be immediately metabolized to other non-toxic compounds, in this case carboxylic acid.
Indeed, we demonstrated such toxic effects by fatty aldehydes and non-toxic effects of carboxylic acids by examining the LCB sensitivity of hfd1 and faa1 faa4 cells ( Figure S3 ).
If hexadecenal was not rapidly metabolized, but instead was first converted to hexadecanal, as shown in Scheme 1 in Figure S5 , toxic effects from these aldehydes might occur.
The hexadecenoic acid generated is converted to hexadecenoyl-CoA ( Figure S5 The ER is the major organelle responsible for synthesizing and metabolizing lipids.
LCBPs are degraded by S1P/LCBP lyase or S1P/LCBP phosphatase in the ER (Ikeda et al., 2004; . Likewise, ALDH3A2 is also localized in the ER (Ashibe et al., 2007) . In addition, localization of Faa1, Faa4, and ACSLs in the ER has been reported (Natter et al., 2005; Soupene and Kuypers, 2008) . Thus, the entire S1P metabolism pathway found in this study occurs in the ER. The ER also contains a trans-2,3-enoyl-CoA reductase (Tsc13 in yeast and TER in mammals), which functions in FA elongation (Kohlwein et al., 2001 ; Moon and Horton, 2003) . Since hexadecenoyl-CoA derived from S1P is also a trans-2,3-enoyl-CoA, these trans-enoyl-CoA reductases might be responsible for the conversion of hexadecenoyl-CoA to palmitoyl-CoA.
LCBs were metabolized to both sphingolipids and glycerolipids in wild type yeast cells, while the glycerolipid pathway was completely blocked in hfd1 cells (Figure 2A ). In contrast,
LCBs were still converted to glycerolipids, although in reduced amounts, in mammalian cells lacking ALDH3A2 (FAA-K1A cells; Figure 5B ). Furthermore, in FAA-K1A cells LCBs were apparently metabolized to the sn-2 acyl group of plasmanylcholine/plasmenylethanolamine, in addition to the sn-1 alkyl/alkenyl groups ( Figure 5B ). Reportedly, FAA-K1A cells exhibit ~10% FALDH activity compared to wild type CHO-K1 cells (James and Zoeller, 1997) . It is possible that trace amounts of the ALDH3A2 mRNA, below the detection limit of our RT-PCR ( Figure 5A ) are expressed in FAA-K1A cells. Alternatively, another FALDH, perhaps another ALDH3 family member, might be responsible for the residual FALDH activity. In FAA-K1A cells, some LCBs were metabolized to the ether-linked glycerolipids plasmenylethanolamine and plasmanylcholine ( Figure 5B ). Generation of these lipids require fatty alcohols as substrates (Nagan and Zoeller, 2001) . Cellular fatty alcohols are mainly produced from acyl-CoAs by the fatty acyl-CoA reductase Far1 (Honsho et al., 2010) , and are utilized in the production of ether-linked glycerolipids or are converted to FAs via fatty aldehydes by a fatty alcohol:NAD oxidoreductase (FAO) complex (Lee, 1979) . Although fatty alcohol dehydrogenase in the FAO complex normally catalyzes the conversion of fatty alcohol to fatty aldehyde, accumulation of fatty aldehydes in FAA-K1A cells may cause an equilibration shift, resulting in a reverse reaction. Although the metabolic pathway for LCB to ether-linked glycerolipids was observed only in the ALDH3A2-null FAA-K1A cells, it is possible that this pathway also functions in certain tissues or cell types where expression levels of ALDH3A2 are low.
In the pathology of SLS, accumulated fatty aldehyde molecules normally metabolized by ALDH3A2 are thought to react with important cellular components and cause cell damage (Rizzo, 2007) . However, the identity of the pathology-causing fatty aldehydes and their origins still remain unclear, although several candidate molecules/pathways have been proposed, including phytol oxidation (van den Brink et al., 2004) and the leukotriene B 4 metabolic pathway (Willemsen et al., 2001 ). We propose here that hexadecenal derived from S1P may contribute to the pathology of SLS, at least partly. Considerable amounts of glycerolipids were detected by [11,12- Figure 5B ). Moreover, Sph kinase, S1P lyase, and ALDH3A2 are all ubiquitously expressed (Ikeda et al., 2004; Liu et al., 2000; Nava et al., 2000; Rogers et al., 1997) , so the Sph/S1P-to-glycerolipid metabolic pathway may be active in most tissues. Thus, we speculate that hexadecenal derived from S1P may account for a relatively large proportion of intracellularly generated fatty aldehydes.
In the presented study, we revealed the entire S1P metabolic pathway. However, future study is required for the identification of the still missing reductase responsible for converting hexadecenoyl-CoA to palmitoyl-CoA. In addition, the S1P metabolite hexadecenal and its involvement in the pathogenesis of SLS should be investigated using Aldh3A2 knockout mice.
EXPERIMENTAL PROCEDURES Yeast Strains, Plasmids, Cell Culture, and Transfection
Cell lines, culture media, and transfection reagents used, as well as construction of S.
cerevisiae strains and of plasmids, are described in the Supplemental Information.
Immunological Assays
Immunoblotting was performed as described previously . PBS, suspended in 6 ml PBS with 5 mM dithiothreitol, and transferred to glass tubes. Lipids were extracted by successive addition and mixing of 22.5 ml chloroform/methanol/HCl (100:200:1, v/v), 7.5 ml chloroform, and 7.5 ml 1% KCl. Phases were separated by centrifugation, and the organic phase was recovered, dried, and suspended in 3.6 ml chloroform/methanol (1:1, v/v) with 1% buthylhydroxytoluene. Samples were then incubated with methanolysis reagent (4 ml 10% methanolic HCl and 0.4 ml 2,2-dimethoxypropane) for 5 hr at 100 ˚C. Generated FA methyl esters were removed from methanol with 8 ml hexane.
Phases were separated by centrifugation, and the hexane phase was discarded. After repeating the hexane extraction thrice, lipids were extracted from the methanol phase by successive addition and mixing of 6 ml chloroform and 6 ml 1% KCl previously . Double bond cleavage assays were performed essentially as described elsewhere (Scarim et al., 1989) . Cultured mammalian cells were labeled with [11, H]Sph or [4,5-3 H]DHS as described previously (Kihara et al., 2003) . Details are described in the Supplemental Information.
In Vitro Enzyme Assays 3xFLAG-SPHK1, 3xFLAG-SPL, or 3xFLAG-ALDH3A2 was expressed in HEK 293T cells, then affinity-purified using anti-FLAG M2 affinity agarose gel. HEK 293T cells were transfected with the pCE-puro 3xFLAG-mSPHK1a, pCE-puro 3xFLAG-mSPL, or pCE-puro 3xFLAG-ALDH3A2 plasmid. Twenty-four hr after transfection, cells were suspended in buffer A (50 mM HEPES-NaOH (pH 7.4), 150 mM NaCl, 10% glycerol, 1x protease inhibitor mixture (Complete TM EDTA free; Roche Diagnostics, Indianapolis, IN), 1 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol) and lysed by sonication. The resulting total cell lysates were subjected to centrifugation at 100,000 g for 30 min at 4 ˚C. The supernatant (soluble fraction) was used for purification of 3xFLAG-SPHK1, and the pellet (membrane fraction) was used for purification of 3xFLAG-SPL and 3xFLAG-ALDH3A2. The pellet was suspended in buffer A by sonication and solubilized with 1% Triton X-100 for 30 min at 4 ˚C. After centrifugation at 100,000 g for 30 min at 4 ˚C, the supernatant (solubilized fraction) was recovered. Anti-FLAG M2 affinity agarose gel was added to the soluble fraction containing 3xFLAG-SPHK1 or to the solubilized fraction containing 3xFLAG-SPL or 3xFLAG-ALDH3A2, and each mixture was incubated over night at 4 ˚C with rotation. Beads were washed twice with buffer A (for 3xFLAG-SPHK1) or buffer A containing 0.1% Triton X-100 (for 3xFLAG-SPL and 3xFLAG-ALDH3A2); bound proteins were eluted with buffer A containing 100 g/ml 3xFLAG peptide with 0.1% Triton X-100 (for 3xFLAG-SPL and 3xFLAG-ALDH3A2) or without (for 3xFLAG-SPHK1).
Sph kinase assays and [11, H]S1P preparation were performed as described previously (Kihara et al., 2003) . In vitro FALDH assays were performed using hexadecanal (Kariya et al., 2005 ) and 2-trans-hexadecenal (Avanti Polar Lipid, Alabaster, AL) as described elsewhere (Kelson et al., 1997) .
For use as a TLC standard, [9,10-3 H]hexadecenoic acid was prepared from [11, H]S1P
using affinity purified 3xFLAG-SPL and 3xFLAG-ALDH3A2. 3xFLAG-SPL and 3xFLAG-ALDH3A2 were incubated for 1 hr at 37 ˚C with [11, H]S1P, complexed with 1 mg/ml (final concentration of 0.2 mg/ml) FA-free BSA, in buffer A containing 0.1% Triton X-100, 100 M NAD + , and 250 M pyridoxal 5'-phosphate. After the reaction, lipids were extracted, dried, and suspended in ethanol.
RT-PCR
RT-PCR was performed using a Super Script One-Step RT-PCR with Platinum Taq (Invitrogen) and primers described in the Supplemental Information.
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